Trademarkia Logo

Canada

C$
VYGLXIA
REGISTERED

on 1 Nov 2023

Last Applicant/ Owned by

BIOHAVEN THERAPEUTICS LTD.

Ritter House, P.O. Box 173, Road TownTortola VG1110

VG

Serial Number

2154393 filed on 13th Sept 2021

Registration Number

TMA1206537 registered on 1st Nov 2023

Registration expiry Date

13th Sept 2031

Correspondent Address

SMART & BIGGAR LP

1000 RUE DE LA GAUCHETIERE OUESTBUREAU 3300MONTREAL

QUÉBEC

CA

H3B4W5

VYGLXIA

Trademark usage description

medicated, pharmaceutical and veterinary preparations, both prescription and over-the-counter, in the nature of for the treatment of central nervous s Read More

Classification Information


Class [005]
Medicated, pharmaceutical and veterinary preparations, both prescription and over-the-counter, in the nature of for the treatment of central nervous system disorders, in the nature of central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, neurologic illnesses in the nature of brain injury, spinal cord injury, seizure disorders, and psychiatric illnesses in the nature of anxiety disorder, depression, Bipolar Disorder, Post-Traumatic Stress Disorder (PTSD), Schizophrenia, Eating Disorders, Disruptive behaviour and dissocial disorders, Neurodevelopmental disorders; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, in the nature of post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, in the nature of post-intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases, in the nature of Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment of aging, progressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, in the nature of glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, in the nature of opioid sparing analgesia, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, in the nature of headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases, in the nature of breath holding in Rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, pseudobulbar affect, levodopa-induced dyskinesias in Parkinson's disease, agitation in AD, disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, in the nature of precision medicine - adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders, in the nature of treatment resistant depression, Post Traumatic Stress Disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, Obsessive Compulsive Disorder (OCD), hoarding, trichotillomania, eating disorders, Generalized Anxiety Disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders, in the nature of spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, Attention Deficit Disorder (ADD), Pervasive Developmental Disorders (PDD), Asperger's syndrome, autism, menopausal hot flashes


Classification kind code

11

Mark Details


Serial Number

2154393

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 22
on 28th Mar 2023
Search Recorded
Submitted for opposition 20
on 28th Mar 2023
Examiner's First Report
Submitted for opposition 256
on 17th Oct 2022
Notification of Possible Opposition Sent
Submitted for opposition 67
on 7th Oct 2022
Agent Name Changed
Submitted for opposition 48
on 11th Jan 2022
Agent Changed
Submitted for opposition 257
on 16th Dec 2021
Designation Notification - Madrid Protocol
Submitted for opposition 31
on 15th Dec 2021
Formalized
Submitted for opposition 1
on 15th Dec 2021
Created
Submitted for opposition 228
on 13th Sept 2021
International Registration
Submitted for opposition 30
on 13th Sept 2021
Filed